Roche has started drug price negotiations with the National Health Insurance Service for its breast cancer drug Perjeta (pertuzumab).

The negotiations are expected to be held on the drugs whose reimbursement standards were set by the Cancer Disease Review Committee in May.

According to industry sources on the 11th, the NHIS recently included Perjeta in its list of drug price negotiation subjects in November. The items subject to drug price negotiation are new drugs, drugs that are not subject to drug price negotiations, and drugs with expanded use. This negotiation appears to be a case of expanded scope of use, as Perjeta was already listed for reimbursement in June 2017.